A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Immune dysregulation is a mechanism contributing to ineffective hematopoiesis in a subset of myelodysplastic syndrome patients. We report the first US multicenter non-randomized, phase II trial examining the efficacy of rabbit(r)-anti-thymocyte globulin using 2.5 mg/kg/day administered daily for 4 doses. The primary end point was hematologic response; secondary end points included duration of response, time to response, time to progression, and tolerance. Nine (33%;95% confidence interval=17%–54%) of the 27 patients treated experienced durable hematologic improvement in an intent-to-treat analysis with a median time to response and median response duration of 75 and 245 days, respectively. While younger age is the most significant factor favoring equine(e)-anti-thymocyte globulin response, treatment outcome on this study was independent of age (P=0.499). A shorter duration between diagnosis and treatment showed a positive trend (P=0.18), but International Prognostic Scoring System score (P=0.150), karyotype (P=0.319), and age-adjusted bone marrow cellularity (P=0.369) were not associated with response classification. Since activated T-lymphocytes are the primary cellular target of anti-thymocyte globulin, a T-cell expression profiling was conducted in a cohort of 38 patients consisting of rabbit and equine-antithymocyte globulin-treated patients. A model containing disease duration, CD8 terminal memory T cells and T-cell proliferation-associated-antigen expression predicted response with the greatest accuracy using a leave-one-out cross validation approach. This profile categorized patients independent of other covariates, including treatment type and age using a leave-one-out-cross-validation approach (75.7%). Therefore, rabbit-anti-thymocyte globulin has hematologic remitting activity in myelodysplastic syndrome and a T-cell activation profile has potential utility classifying those who are more likely to respond (NCT00466843 clinicaltrials.gov).

[1]  Sheng Wei,et al.  Induction of myelodysplasia by myeloid-derived suppressor cells. , 2013, The Journal of clinical investigation.

[2]  F. Bertucci,et al.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts , 2013, Haematologica.

[3]  Sheng Wei,et al.  Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency , 2012, Leukemia.

[4]  J. Maciejewski,et al.  Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome , 2012, The Journal of Immunology.

[5]  A. Risitano.  Immunosuppressive therapies in the management of acquired immune-mediated marrow failures , 2012, Current opinion in hematology.

[6]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[7]  P. Hohensinner,et al.  Telomere dysfunction, autoimmunity and aging. , 2011, Aging and disease.

[8]  A. Ganser,et al.  Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. O. Baratti,et al.  Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts , 2010, BMC Medical Genomics.

[10]  B. Storer,et al.  Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study , 2010, British journal of haematology.

[11]  N. Young,et al.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Weyand,et al.  Rejuvenating the immune system in rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[13]  Je-in Youn,et al.  Regulatory myeloid suppressor cells in health and disease. , 2009, Cancer research.

[14]  Sheng Wei,et al.  Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome , 2009, Leukemia.

[15]  H. Kantarjian,et al.  Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome , 2009, Leukemia.

[16]  John Barrett,et al.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Mizoguchi,et al.  Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. , 2007, Blood.

[18]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[19]  G. Mufti,et al.  Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin , 2007, Leukemia.

[20]  Li Wang,et al.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.

[21]  Xingmin Feng,et al.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. , 2006, Blood.

[22]  E. Hellström-Lindberg.  Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. , 2005, Hematology. American Society of Hematology. Education Program.

[23]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[24]  H. Deeg,et al.  Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. , 2004, Leukemia research.

[25]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[26]  A. Barrett,et al.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.

[27]  A. Dispenzieri,et al.  Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. , 2003, Blood.

[28]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[29]  N. Young,et al.  Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. , 2002, Blood.

[30]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[31]  Pamela S. Ohashi,et al.  T-cell signalling and autoimmunity: molecular mechanisms of disease , 2002, Nature Reviews Immunology.

[32]  A. Ganser,et al.  Favourable response to antithymocyte or antilymphocyte globulin in low‐risk myelodysplastic syndrome patients with a ‘non‐clonal’ pattern of X‐chromosome inactivation in bone marrow cells , 2002, European journal of haematology.

[33]  K. Shimoda,et al.  Immunosuppressive therapy for patients with refractory anemia , 2001, Annals of Hematology.

[34]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[35]  A. Barrett,et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles , 1998, British journal of haematology.

[36]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[37]  J. G. van den Tweel,et al.  Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.

[38]  R. Kusec,et al.  Telomere length in myelodysplastic syndromes , 1995, American journal of hematology.

[39]  B STEINMANN,et al.  [Aging and disease]. , 1963, Schweizerische medizinische Wochenschrift.